May 25, 2017 announcements AI enabled research shows delay in onset of motor neurone disease Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results. ARTIFICIAL INTELLIGENCE , DRUG DISCOVERY
Apr 11, 2017 announcements BenevolentAI agrees partnership with medical research charity MRC technology London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies. DRUG DISCOVERY , SCIENCE , BIOMEDICAL , ARTIFICIAL INTELLIGENCE , BENEVOLENTAI
Feb 21, 2017 articles Bold claims for AI are hard to compute for economists The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany. ARTIFICIAL INTELLIGENCE , TECH , BUSINESS , KEN MULVANY , DISRUPTIVE , TRENDS , BENEVOLENTAI
Jan 11, 2017 announcements British technology firm appointed to the global ‘AI 100’ for advancing artificial intelligence in drug discovery Revealed at the 2017 CB Insights Innovation Summit, Santa Barbara, California CB INSIGHTS , AI 100 , INNOVATION , UNICORN
Jul 5, 2017 articles Could AI help treat Motor Neurone Disease? We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough. DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , ALS , MOTOR NEURONE DISEASE
